Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility and effectiveness of the prolonged use of eltrombopag in addition to immunosuppression in patients with acquired aplastic anemia: a single-center real-life experience.
Carpenedo M, Zappaterra A, Del Castello L, Ferrari B, Cotilli G, Bernasconi DP, Pezzatti S, Sacco F, Borin L, Carrer A, Verga L, Brioschi F. Carpenedo M, et al. Among authors: borin l. Platelets. 2024 Dec;35(1):2415483. doi: 10.1080/09537104.2024.2415483. Epub 2024 Oct 16. Platelets. 2024. PMID: 39641636 Free article.
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment.
Trojani A, Pungolino E, Rossi G, D'Adda M, Lodola M, Camillo BD, Perego A, Turrini M, Orlandi E, Borin L, Iurlo A, Malato S, Spina F, Latargia ML, Lanza F, Artale S, Anghilieri M, Carraro MC, Canal G, Morra E, Cairoli R. Trojani A, et al. Among authors: borin l. Cancer Biomark. 2017 Dec 12;21(1):41-53. doi: 10.3233/CBM-170209. Cancer Biomark. 2017. PMID: 29036785
Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
Arienti F, Gambacorti-Passerini C, Borin L, Rivoltini L, Orazi A, Pogliani EM, Corneo G, Parmiani G. Arienti F, et al. Among authors: borin l. Ann Oncol. 1992 Feb;3(2):155-62. doi: 10.1093/oxfordjournals.annonc.a058133. Ann Oncol. 1992. PMID: 1606087 Free article.
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Scappini B, Gianfaldoni G, Caracciolo F, Mannelli F, Biagiotti C, Romani C, Pogliani EM, Simonetti F, Borin L, Fanci R, Cutini I, Longo G, Susini MC, Angelucci E, Bosi A. Scappini B, et al. Among authors: borin l. Am J Hematol. 2012 Dec;87(12):1047-51. doi: 10.1002/ajh.23308. Epub 2012 Aug 1. Am J Hematol. 2012. PMID: 23151979 Free article. Clinical Trial.
Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and potential predictive role in infectious complications.
Belotti A, Duca L, Borin L, Realini S, Renso R, Parma M, Pioltelli P, Pogliani E, Cappellini MD. Belotti A, et al. Among authors: borin l. Leuk Res. 2015 Jan;39(1):88-91. doi: 10.1016/j.leukres.2014.11.003. Epub 2014 Nov 15. Leuk Res. 2015. PMID: 25435028 Clinical Trial.
54 results